Olmesartán/Hidroclorotiazida Combix (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxomil, the active ingredient in Olmesartán/Hidroclorotiazida Combix, is a angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, and is intended for adult patients. GNH USA supplies Olmesartán/Hidroclorotiazida Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán/Hidroclorotiazida Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil/Hydrochlorothiazide is used in the management of high blood pressure through combined renin‑angiotensin blockade and diuresis.

- Hypertension: improves blood pressure control when monotherapy is insufficient. - Heart failure with reduced ejection fraction: assists in volume management and afterload reduction as part of guideline‑directed therapy. - Diabetic nephropathy: helps slow progression of renal impairment by lowering systemic pressure. - Post‑myocardial infarction hypertension: supports secondary prevention by maintaining target pressures. - Chronic kidney disease stage 3–4: contributes to proteinuria reduction and pressure control. - Resistant hypertension: provides an additional mechanism when other agents have failed.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Before starting therapy, clinicians should evaluate patient history and monitor relevant parameters.

- Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid unless benefits outweigh risks. - Concomitant drugs: review for potential additive potassium‑sparing effects. - Gout: use cautiously in patients with a history of hyperuricemia. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Hydrochlorothiazide may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Aliskiren (combined renin‑angiotensin inhibition may cause renal impairment). - Potassium‑sparing diuretics or supplements (risk of hyperkalemia). - Lithium (increased lithium levels and toxicity).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) (may reduce antihypertensive effect and affect renal function). - ACE inhibitors or other ARBs (additive hypotensive effect). - Antidiabetic agents (enhanced glucose‑lowering effect, risk of hypoglycaemia).